Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

An Immunogenicity and Safety Study of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants

22. januar 2019 opdateret af: Sinovac Biotech Co., Ltd

A Randomized, Double-blind, Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants

The purpose of this phase III study is to evaluate the immunogenicity and safety of Sabin Inactivated Poliovirus Vaccine (Vero cell) in 2-month-old infants.

Studieoversigt

Status

Afsluttet

Betingelser

Detaljeret beskrivelse

The study is a randomized, double-blind, controlled randomized, double-blind, controlled clinical trial clinical trial. The purpose of this study is to evaluate the immunogenicity and safety of Sabin Inactivated Poliovirus Vaccine (Vero cell) manufactured by Sinovac Vaccine Technology Co., Ltd in 2-month-old infants. The control vaccine is a commercialized Inactivated Poliovirus Vaccine manufactured by Sanofi Pasteur company. 1200 healthy infants between 60-90 days will be randomly assigned into experimental group or control group in the ratio 1:1.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

1200

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Jiangsu
      • Pizhou, Jiangsu, Kina, 221300
        • Pizhou county Center for Disease Control and Prevention

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

1 måned til 2 måneder (Barn)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Healthy volunteer between 60-90 days old;
  • Healthy volunteers who fulfill all the required conditions for receiving the investigational vaccine as established by medical history and clinical examination and determined by investigators;
  • Proven legal identity;
  • Participants or guardians of the participants should be capable of understanding the written consent form, and such form should be signed prior to enrolment;
  • Complying with the requirement of the study protocol;

Exclusion Criteria:

  • Prior vaccination with Poliovirus Vaccine;
  • History of allergy to any vaccine, or any ingredient of the vaccine, or serious adverse reaction(s) to vaccination, such as urticaria, dyspnea, angioneurotic edema, abdominal pain, etc;
  • Congenital malformation, developmental disorders, genetic defects, or severe malnutrition;
  • Autoimmune disease or immunodeficiency/immunosuppressive;
  • Severe nervous system disease (epilepsy, seizures or convulsions) or mental illness;
  • Diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or platelet abnormalities) , or obvious bruising or coagulation disorders;
  • Any immunosuppressant, cytotoxic medicine, or inhaled corticosteroids (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute non-complicated dermatitis) prior to study entry;
  • Blood product prior to study entry;
  • Any other investigational medicine(s) within 30 days prior to study entry;
  • Any live attenuated vaccine within 14 days prior to study entry;
  • Any subunit vaccine or inactivated vaccine within 7 days prior to study entry;
  • Acute disease or acute stage of chronic disease within 7 days prior to study entry;
  • Axillary temperature > 37.0 °C;
  • Any other factor that suggesting the volunteer is unsuitable for this study based on the opinions of investigators;

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Experimental Group

The investigational vaccine was manufactured by Sinovac Vaccine Technology Co., Ltd.

Intervention: investigational sIPV

Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Single intramuscular injection of the investigational vaccine (0.5 ml) at 18 months; Intervention: investigational sIPV
Aktiv komparator: Control Group
The control vaccine was manufactured by Sanofi Pasteur Company. Intervention: control IPV
Three intramuscular injections of the control vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Single intramuscular injection of the control vaccine (0.5 ml) at 18 months; Intervention:control IPV

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
The seroconversion rates (SCRs) of each group after primary immunization.
Tidsramme: 90 days
Subjects whose pre-immune antibody level < 1:8 and post-immune antibody level ≥ 1:8, or those whose pre-immune antibody level ≥ 1:8 and the increase of post-immune antibody level ≥ 4 folds are considered seroconverted. Primary vaccination schedule: 3 doses with one month interval between doses (i.e., month 0, 1, 2).
90 days

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
The incidences of solicited adverse events (AEs) of each group.
Tidsramme: 7 days
Solicited AEs occurred within 7 days after each injection will be collected.
7 days
The incidences of unsolicited adverse events (AEs) of each group.
Tidsramme: 30 days
Unsolicited AEs occurred within 30 days after each injection will be collected.
30 days
The incidence of serious adverse events (SAEs) during the period of safety monitoring of each group.
Tidsramme: 90-420 days.
SAEs during the period of safety monitoring will be collected.
90-420 days.
The post-immune antibody positive rate of each group after primary immunization.
Tidsramme: 90 days
Subjects whose post-immune antibody level ≥ 1:8 are considered antibody positive. Primary vaccination schedule: 3 doses with one month interval between doses (i.e., month 0, 1, 2).
90 days
The post-immune geometric mean titer (GMT) of each group after primary immunization.
Tidsramme: 90 days.
GMT of each group after primary immunization which lasts 60 days.
90 days.
The geometric mean fold increase (GMI) of each group after primary immunization.
Tidsramme: 90 days
The GMI is the increase of post-immune GMT from pre-immune GMT.
90 days
The percentage of subjects with antibody ≥ 1:64 of each group after primary immunization.
Tidsramme: 90 days
Percentage of subjects with antibody ≥ 1:64 of each group after three-dose
90 days
The antibody positive rate of each group before booster dose.
Tidsramme: 420 days
Subjects whose post-immune antibody level ≥ 1:8 are considered antibody positive. A booster dose at the age of 18months.
420 days
The geometric mean titer (GMT) of each group before booster dose.
Tidsramme: 420 days.
GMT of each group before booster dose which occurred at the age of 18months.
420 days.
The geometric mean fold increase (GMI) of each group before booster dose.
Tidsramme: 420 days
The GMI is the increase of post-immune GMT from pre-i mmune GMT.
420 days
The percentage of subjects with antibody ≥ 1:64 of each group before booster dose.
Tidsramme: 420 days
Percentage of subjects with antibody ≥ 1:64 of each group before booster dose which occurred at the age of 18months.
420 days
The post-immune antibody positive rate of each group after booster dose.
Tidsramme: 570 days

Subjects whose post-immune antibody level ≥ 1:8 are co

nsidered antibody positive

570 days
The post-immune geometric mean titer (GMT) of each group after booster dose.
Tidsramme: 570 days
GMT of each group after booster dose. The booster dose at the age of 18months
570 days
The geometric mean fold increase (GMI) of each group after booster dose.
Tidsramme: 570 days
The GMI is the increase of post-immune GMT from pre-immune GMT.
570 days
The percentage of subjecs with antibody ≥ 1:64 of each group after booster dose.
Tidsramme: 570 days
Percentage of subjecs with antibody ≥ 1:64 of each group after booster dose which occurred at the age of 18months.
570 days

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

8. august 2017

Primær færdiggørelse (Faktiske)

18. oktober 2017

Studieafslutning (Faktiske)

18. april 2018

Datoer for studieregistrering

Først indsendt

4. maj 2018

Først indsendt, der opfyldte QC-kriterier

4. maj 2018

Først opslået (Faktiske)

16. maj 2018

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

25. januar 2019

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

22. januar 2019

Sidst verificeret

1. januar 2019

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner